R

REGENXBIO
D

RGNX

9.19000
USD
-0.44
(-4.52%)
Market Closed
Volume
0
EPS
-5
Div Yield
-
P/E
-2
Market Cap
454,199,098
OverviewSignalsIdeasNews
Related Instruments
    ALNY
    ALNY
    -22.650
    (-8.77%)
    235.480 USD
    B
    BLUE
    -0.04270
    (-11.74%)
    0.32090 USD
    C
    CRSP
    0.360
    (0.77%)
    47.280 USD
    E
    EDIT
    -0.11500
    (-4.14%)
    2.66500 USD
    N
    NTLA
    -1.165
    (-7.71%)
    13.955 USD
    Q
    QURE
    -0.55000
    (-8.14%)
    6.21000 USD
    R
    RARE
    -2.865
    (-6.02%)
    44.745 USD
    S
    SGMO
    -0.10000
    (-4.67%)
    2.04000 USD
    S
    SRPT
    -4.470
    (-4.10%)
    104.600 USD
    VRTX
    VRTX
    -18.53
    (-3.83%)
    450.37 USD
    More
News

Title: REGENXBIO

Sector: Healthcare
Industry: Biotechnology
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.